| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
11,270,000 |
| Market
Cap: |
290.99(M) |
| Last
Volume: |
197,427 |
Avg
Vol: |
196,876 |
| 52
Week Range: |
$13.82 - $26.35 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile XOMA is a biotech royalty aggregator. Co. has a portfolio of economic rights to milestone and royalty payments associated with partnered pre-commercial therapeutic candidates. Co.'s portfolio was built through licensing its proprietary products and platforms from its discovery and development business, combined with acquisitions of rights to milestones and royalties.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
14,600 |
117,800 |
| Total Buy Value |
$0 |
$0 |
$268,048 |
$2,088,813 |
| Total People Bought |
0 |
0 |
2 |
3 |
| Total Buy Transactions |
0 |
0 |
13 |
21 |
| Total Shares Sold |
0 |
0 |
0 |
27,000 |
| Total Sell Value |
$0 |
$0 |
$0 |
$809,425 |
| Total People Sold |
0 |
0 |
0 |
2 |
| Total Sell Transactions |
0 |
0 |
0 |
2 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Scannon Patrick J Md Phd |
Exec. VP & CSO |
• • – |
2016-03-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,500 |
243,727 |
|
- |
|
| Varian John |
CEO |
• • – |
2016-03-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
36,907 |
1,189,695 |
|
- |
|
| Scannon Patrick J Md Phd |
Exec. VP & CSO |
• • – |
2016-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
140,000 |
234,227 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2016-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
198,330 |
338,654 |
|
- |
|
| Burns Thomas M. |
VP, Finance & Chief Financial |
• – – |
2016-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
108,560 |
202,320 |
|
- |
|
| Neal James R |
VP Business Development |
– – – |
2016-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
248,954 |
431,152 |
|
- |
|
| Varian John |
CEO |
• • – |
2016-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
541,600 |
1,152,788 |
|
- |
|
| Scannon Patrick J Md Phd |
Exec. VP & CSO |
• • – |
2016-02-01 |
4 |
AS |
$1.01 |
$8,080 |
D/D |
(8,000) |
94,227 |
|
- |
|
| Scannon Patrick J Md Phd |
Exec. VP & CSO |
• • – |
2015-12-28 |
4 |
AS |
$1.37 |
$10,937 |
D/D |
(8,000) |
102,227 |
|
- |
|
| Limber Joseph M |
Director |
– • – |
2015-12-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,600 |
73,173 |
|
- |
|
| Scannon Patrick J Md Phd |
Exec. VP & CSO |
• • – |
2015-11-23 |
4 |
AS |
$1.35 |
$10,800 |
D/D |
(8,000) |
110,227 |
|
- |
|
| Scannon Patrick J Md Phd |
Exec. VP & CSO |
• • – |
2015-10-26 |
4 |
AS |
$1.04 |
$8,358 |
D/D |
(8,000) |
118,227 |
|
- |
|
| Varian John |
CEO |
• • – |
2015-08-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
94,573 |
611,188 |
|
- |
|
| Varian John |
CEO |
• • – |
2015-08-14 |
4 |
D |
$0.83 |
$29,838 |
D/D |
(35,799) |
516,615 |
|
- |
|
| Scannon Patrick J Md Phd |
Exec. VP & CSO |
• • – |
2015-08-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,264 |
126,227 |
|
- |
|
| Scannon Patrick J Md Phd |
Exec. VP & CSO |
• • – |
2015-08-14 |
4 |
D |
$0.83 |
$5,132 |
D/D |
(6,157) |
109,963 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2015-08-14 |
4 |
D |
$0.83 |
$9,003 |
D/D |
(10,801) |
138,292 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2015-08-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
26,748 |
149,093 |
|
- |
|
| Neal James R |
VP Business Development |
– – – |
2015-08-14 |
4 |
D |
$0.83 |
$7,557 |
D/D |
(9,067) |
175,402 |
|
- |
|
| Baker Julian |
Former 10% owner |
– – – |
2015-07-22 |
4 |
S |
$1.09 |
$12,017,500 |
I/I |
(11,000,000) |
90,538 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2015-07-15 |
4 |
AS |
$4.60 |
$22,992 |
D/D |
(5,000) |
122,345 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2015-07-15 |
4 |
OE |
$3.04 |
$15,200 |
D/D |
5,000 |
127,345 |
|
- |
|
| Varian John |
CEO |
• • – |
2015-07-15 |
4 |
AS |
$4.49 |
$44,869 |
D/D |
(10,000) |
552,414 |
|
- |
|
| Varian John |
CEO |
• • – |
2015-07-15 |
4 |
OE |
$1.24 |
$12,400 |
D/D |
10,000 |
562,414 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2015-07-10 |
4 |
AS |
$4.55 |
$131,985 |
D/D |
(29,000) |
122,345 |
|
- |
|
594 Records found
|
|
Page 8 of 24 |
|
|
0.48 (1.89%) 
